- Home
- GNPX vs KLTO Comparison
GNPX vs KLTO Comparison
Compare GNPX & KLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNPX
- KLTO
- Stock Information
- Founded
- GNPX 2009
- KLTO 2019
- Country
- GNPX United States
- KLTO United States
- Employees
- GNPX N/A
- KLTO N/A
- Industry
- GNPX Biotechnology: Pharmaceutical Preparations
- KLTO
- Sector
- GNPX Health Care
- KLTO
- Exchange
- GNPX Nasdaq
- KLTO NYSE
- Market Cap
- GNPX 7.5M
- KLTO 7.1M
- IPO Year
- GNPX 2018
- KLTO N/A
- Fundamental
- Price
- GNPX $0.29
- KLTO $0.21
- Analyst Decision
- GNPX
- KLTO
- Analyst Count
- GNPX 0
- KLTO 0
- Target Price
- GNPX N/A
- KLTO N/A
- AVG Volume (30 Days)
- GNPX 1.8M
- KLTO 35.4M
- Earning Date
- GNPX 05-12-2025
- KLTO 05-15-2025
- Dividend Yield
- GNPX N/A
- KLTO N/A
- EPS Growth
- GNPX N/A
- KLTO N/A
- EPS
- GNPX N/A
- KLTO N/A
- Revenue
- GNPX N/A
- KLTO N/A
- Revenue This Year
- GNPX N/A
- KLTO N/A
- Revenue Next Year
- GNPX N/A
- KLTO N/A
- P/E Ratio
- GNPX N/A
- KLTO N/A
- Revenue Growth
- GNPX N/A
- KLTO N/A
- 52 Week Low
- GNPX $0.22
- KLTO $0.11
- 52 Week High
- GNPX $3.97
- KLTO $0.99
- Technical
- Relative Strength Index (RSI)
- GNPX 50.37
- KLTO N/A
- Support Level
- GNPX $0.26
- KLTO N/A
- Resistance Level
- GNPX $0.37
- KLTO N/A
- Average True Range (ATR)
- GNPX 0.04
- KLTO 0.00
- MACD
- GNPX 0.00
- KLTO 0.00
- Stochastic Oscillator
- GNPX 35.04
- KLTO 0.00
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
About KLTO KLOTHO NEUROSCIENCES INC
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.